Use of methylphenidate in as add on treatment in patient with Obsessve-Compulsive Disorder

Effectiveness and safety of Selective serotonin Reuptake inhibitor (SSRI) alone vs SSRI with Methylphenidate sustained release in the patients with moderate to severe obsessive compulsive disorder(OCD) - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061995

Enrollment

Registered

2024-01-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F422- Mixed obsessional thoughts and acts

Interventions

Intervention1: Methylphenidate with SSRI: In this arm Methylphenidate(20-40) will be added from beginning to optimal dose of SSRI Control Intervention1: Selective Serotonin Reuptake Inhibitors : SSRIs

Eligibility

Inclusion criteria

Inclusion criteria: Patients with OCD disorder who fulfill the diagnostic criteria according to DSM-5. Patient with Total score more than 16 in Yale-Brown obsessive-compulsive disorder scale. Patients aged between 18-85 years. Subjects who Provide written informed consent, willing and able to comply with all aspects of the protocol

Exclusion criteria

Exclusion criteria: Patient with prior allergic reaction on exposure to Methylphenidate OCD patients with psychiatric illness except depression and anxiety Substance abuse or Dependence within the past 6 months except nicotine History of a seizure disorder or other major neurologic disease. Patients with psychiatric Instability that made participants potentially unsafe in the evaluating psychiatrists judgment. Patients with pregnancy or breastfeeding Patients with known chronic medical illness like, Diabetes Mellitus, Hypertension, Cerebro-vascular Accident, Ischemic Heart Disease, Coronary Artery Disease etc. Patients not in a condition to give written informed consent E.g.: Delirium, intellectual disability etc.

Design outcomes

Primary

Measure	Time frame
To assess the effectiveness of augmentation of SSRI with Methylphenidate in patients with OCDTimepoint: Baseline, 15 days, 1 month & 2 months	—

Secondary

Measure	Time frame
1. To assess tolerability of Methylphenidate in patients with OCD. 2. To assess safety of Methylphenidate in patients with OCD. Timepoint: Baseline, 15 days, 1 month & 2 months	—

Countries

India

Contacts

Public ContactBhoomi Jodhani

MGM Medical College and Hospital

dr.manik.bhise@gmail.com9823703068

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026